Drug intelligence / Profile preview

paracetamol + tramadol hydrochloride

Development stage
Unknown
Lead developer
Shaanxi Jiuzhou Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Shiliqi is a fixed-dose combination analgesic containing paracetamol (acetaminophen) and tramadol hydrochloride. Developed by Shaanxi Jiuzhou Pharmaceutical, it is a generic version of the reference drug ULTRACET, indicated for the management of moderate to severe acute pain. Tramadol hydrochloride is a centrally acting synthetic opioid analgesic that exerts its effect through mu-opioid receptor agonism and the inhibition of the reuptake of norepinephrine and serotonin. Paracetamol is a non-opioid, non-salicylate analgesic and antipyretic that likely acts by inhibiting prostaglandin synthesis in the central nervous system. The combination of these two agents provides a multi-modal approach to pain management, offering rapid onset from paracetamol and sustained relief from tramadol.

Brand names
Shiliqi
Other names
acetaminophen + tramadol hydrochlorideTramadol Hydrochloride and Paracetamol Tablets
02

Targets

MOR (Mu opioid receptor)NET (Norepinephrine Transporter)PGHS-1 (Prostaglandin G/H Synthase 1)SERT (Sodium-dependent serotonin transporter)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on paracetamol + tramadol hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + tramadol hydrochloride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call